<DOC>
	<DOCNO>NCT00005261</DOCNO>
	<brief_summary>To determine whether low total urinary kallikrein activity prospectively associate new hypertension onset elevate blood pressure .</brief_summary>
	<brief_title>Urinary Kallikrein Hypertension : A Prospective Study</brief_title>
	<detailed_description>BACKGROUND : Statistical evidence find dominant major gene segregate large pedigree high urinary kallikrein level protect hypertension explain 51 percent variance total urinary kallikrein ( TUK ) . In normotensive adult pediatric pedigree member , low urinary kallikrein activity associate positive family history hypertension , stroke , and/or coronary disease . DESIGN NARRATIVE : The presence previously report dominant major gene infer segregation analysis total urinary kallikrein activity ( TUK ) select pedigree verify already collect frozen urine specimen . Subjects rescreened obtain measured nine year follow-up blood pressure data . Individuals classify assign baseline TUK genotype test determine whether low TUK prospectively associate new hypertension onset elevate blood pressure . Because major gene effect implicate , available probe structural kallikrein gene relate product regulate kallikrein test genetic linkage TUK level . Correlations 600 variable measure baseline pedigree twin test analyze strong familiality environment , refine genetic analysis well assign genotype , detect gene-environment interaction . All baseline variable except kallikrein , aldosterone , prostaglandin measurement frozen urine follow-up blood pressure already collect . TUK may marker renal , cellular physiological abnormality influence TUK expression susceptibility hypertension . Therefore , relationship TUK urinary aldosterone , prostaglandin E excretion already measure urinary electrolyte , plasma renin activity , baseline reactive blood pressure determine . Genetic segregation analysis perform urinary variable variable closely associate TUK .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>